

Molecule	Originator brand	Therapeutic area / Indication	Strengths	Administration	Form	Main sector ¹	Type of dossier	Expected launch ²	Availability for submission
Caspofungin	Cancidas® by Merck	Antifungal, systemic	50 mg, 70 mg	Parenteral	Powder for solution for infusion	Hospital	EU-CTD	Commercial	Available
Anidulafungin	Ecalta® by Pfizer	Antifungal, systemic	100 mg	Parenteral	Powder for solution for infusion	Hospital	EU-CTD	Commercial	Available
Micafungin	Mycamine® by Astellas	Antifungal, systemic	50 mg, 100 mg	Parenteral	Powder for solution for infusion	Hospital	EU-CTD	Commercial	Available
Tigecyclin	Tygacil® by Pfizer	Antibacterial, systemic	50 mg	Parenteral	Powder for solution for infusion	Hospital	EU-CTD	Commercial / 03.2026 (FDF)	Available
Rivaroxaban	Xarelto® by Bayer	Anticoagulant	2.5 mg, 10 mg, 15 mg, 20 mg	Oral	Film-coated tablets	Retail	EU-CTD	04.2024 / 01.2026	Available
Ticagrelor	Brilique® by AstraZeneca	Anticoagulant	60 mg, 90 mg	Oral	Film-coated tablets	Retail	EU-CTD	12.2024	Available
Tafamidis Meglumine	Vyndaqel® by Pfizer	Amyloidosis	20 mg	Oral	Soft-gel capsules	Mixed	EU-CTD	11.2026	Q3'2023
Tafamidis	Vyndaquei® / V~max® by Pfizer	Amyloidosis	61 mg	Oral	Soft-gel capsules	Mixed	EU-CTD & US-CTD	US: 04.2029 EU: 2031	ANDA 05.2023 EU Q4'2023
Macitentan	Opsumit® by Actelion	Pulmonary hypertension	10 mg	Oral	Film-coated tablets	Mixed	EU-CTD	12.2026	Q4'2023
Osimertinib	Tagrisso® by AstraZeneca	Non-small cell lung cancer	40 mg, 80 mg	Oral	Film-coated tablets	Mixed	EU-CTD	07.2032	In development
Baricitinib	Olumiant® by Eli Lilly	Rheumatoid arthritis	2 mg, 4 mg	Oral	Film-coated tablets	Mixed	EU-CTD	02.2032	In development
Isavuconazol	Cresemba® by Basilea	Antimycotic	100 mg	Oral	Hard capsules	Hospital	EU-CTD	2026	In development
			200 mg	Parenteral	Powder for solution for infusion	Hospital	EU-CTD		In development
Carfilzomib	Kyprolis® by Amgen	Multiple myeloma	10 mg, 30 mg, 60 mg	Parenteral	Powder for solution for infusion	Hospital	EU-CTD	08.2030	In development

¹ Main sector is based on IMS sales distribution by SU in Europe.

² Expected launch date applies for market entry of generic products in major European countries. Please check specific patent situation in any particular country of interest.

For further information, please contact: pharma.licensing@selectchemie.com

Disclaimer: None of the products will be offered for sale or supply to countries in which they were affected by valid and effective patents in force.